相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
RANKL Is Involved in Runx2-Triggered Hepatic Infiltration of Macrophages in Mice with NAFLD Induced by a High-Fat Diet
Li Zhong et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives
Vasiliki Venetsanaki et al.
CURRENT VASCULAR PHARMACOLOGY (2019)
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes
A. Mantovani et al.
DIABETES & METABOLISM (2019)
Off-label uses of denosumab in metabolic bone diseases
Stergios A. Polyzos et al.
BONE (2019)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Nonalcoholic Fatty Liver Disease: Is It Time for Combination Treatment and a Diabetes-Like Approach?
Stergios A. Polyzos et al.
HEPATOLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case-control study in China
Yixin Niu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report
Ayumu Takeno et al.
BMC ENDOCRINE DISORDERS (2016)
Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
Vagelis Rinotas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus
Stefan Kiechl et al.
NATURE MEDICINE (2013)
Nonalcoholic Fatty Liver Disease Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease
Stergios A. Polyzos et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2012)
Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction
Subhra Karmakar et al.
JOURNAL OF OSTEOPOROSIS (2011)
Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
Stergios A. Polyzos et al.
CURRENT MOLECULAR MEDICINE (2009)
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
G Eghbali-Fatourechi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)